This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Grading the Twitterverse's 2013 Biotech Stock Picks

Stocks in this article: AMRN CELG SRPT ARNA SGMO MNKD ACHN APPA CYTK TRGT FOLD INCY ONXX

BOSTON ( TheStreet) -- Last January, I invited my Twitter followers to make their own biotech stock predictions for 2013. Let's check in to see whose crystal ball was in fine working order.

Amarin (AMRN) has been a big loser, which makes @Sport234a2b a big winner!

Nope, but Targacept (TRGT) is up almost 30% this year despite, basically, doing nothing. TRGT Chart TRGT data by YCharts

Cytokinetics (CYTK) closed Friday at $8.18, so you got that right, even after factoring in the 1-for-6 reverse stock split. No ALS data or partner yet and that heart-failure drug isn't looking so hot.

Fail.

Sarepta Therapeutics (SRPT - Get Report) a volatile stock? You betcha. We're still waiting for the actual eteplrisen filing and expected FDA panel, which are now 2014 events.

Amicus Therapeutics (FOLD) and Incyte (INCY) are still single.

Martin was kidding, I hope.

I hesitate to congratulate Ben for his prescient prediction because it will only swell his already-robust ego.

A.P. Pharma (APPA) is not enjoying 2013: APPA Chart APPA data by YCharts

But yes, the "A" drug launches pretty much suck, so good on 'ya!

MannKind (MNKD) the stock of the year? Not a chance, but shares are up 146% so you get half credit.

Excellent. You were spot on.

Too easy.

Nope. Very little hepatitis C deal-making this year, but Achillion Pharma's (ACHN) sovaprevir ('1625) remains unpartnered. Correct.

Let's take a look at the year-to-date stock performance of the big-cap biotechs: CELG Chart CELG data by YCharts

Celgene (CELG - Get Report)... Booyah!

Arena Pharma's (ARNA - Get Report) Belviq launch has been a near disaster. Half credit.

O-fer. Better luck next year.

I don't know what Opko Health (OPK) actually did this year to validate its diagnostics business, but the stock worked. OPK Chart OPK data by YCharts

Congrats. Well done.

Vikram wins best prediction of 2013.

It has been a good year for deal making, maybe not as much as M&A as you predicted however.

The chart says: "Incorrect!" SGMO Chart SGMO data by YCharts

Nice call on Anacor Pharma (ANAC), but it does illustrate some of the absurd stock moves during this year's biotech bubble. ANAC Chart ANAC data by YCharts

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs